Skip to main content
. 2015 Feb 4;6(10):8019–8035. doi: 10.18632/oncotarget.3139

Figure 1. Network-based identification of PIM-modulated apoptotic pathways and screening of candidate PIM inhibitors.

Figure 1

(A) Four heterogeneous types of evidence were integrated and calculated as the likelihood ratios.   (B) ROC curves for evaluating the performances. NB-Loc and NB-Ran denote the Naïve Bayesian model that integrate all the evidence sources and are based on the negative set Loc-NRS and Ran-NRS, respectively. The prediction model is based on the negative reference set Loc-NRS except the NB-Ran model that uses Ran-NRS as the negative reference set. TP/FP ratios (true positive versus false positive) are calculated at different LR cutoffs. (C) The PPI of PIM kinases. (D) The MTT assay of candidate compounds.